100 related articles for article (PubMed ID: 7821341)
1. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel.
Romey G; Bois P; Lazdunski M
Eur J Pharmacol; 1994 Sep; 263(1-2):101-5. PubMed ID: 7821341
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels.
Romey G; Lazdunski M
J Pharmacol Exp Ther; 1994 Dec; 271(3):1348-52. PubMed ID: 7996445
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of a novel Ca2+ entry blocker: SR 33805.
Chatelain P; Clinet M; Polster P; Christophe B; Manning AS
Eur J Pharmacol; 1993 Aug; 246(3):181-93. PubMed ID: 8223943
[TBL] [Abstract][Full Text] [Related]
4. Indolizinsulphones. A class of blockers with dual but discriminative effects on L-type Ca2+ channel activity and excitation-contraction coupling in skeletal muscle.
Bois P; Romey G; Lazdunski M
Pflugers Arch; 1991 Dec; 419(6):651-6. PubMed ID: 1724076
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory action of SR33557 on L-type calcium current in single ventricular myocytes of rat.
Yasui K; Palade P
Br J Pharmacol; 1995 Jan; 114(2):468-74. PubMed ID: 7881746
[TBL] [Abstract][Full Text] [Related]
6. SR33805, a Ca2+ antagonist with length-dependent Ca2+ -sensitizing properties in cardiac myocytes.
Cazorla O; Lacampagne A; Fauconnier J; Vassort G
Br J Pharmacol; 2003 May; 139(1):99-108. PubMed ID: 12746228
[TBL] [Abstract][Full Text] [Related]
7. Effect of SR33805 on barium current and asymmetric intramembrane charge movement in freshly dissociated mouse cerebellar Purkinje neurons.
Melliti K; Bournaud R; Bastide B; Hidalgo J; Shimahara T
Neurosci Lett; 1996 Oct; 216(3):167-70. PubMed ID: 8897484
[TBL] [Abstract][Full Text] [Related]
8. Effect of fantofarone, a new Ca2+ channel antagonist, on angioplasty-induced vasospasm in an atherosclerotic rabbit model.
Dongay B; Dol-Gleizes F; Herbert JM
Biochem Pharmacol; 1998 Jun; 55(12):2047-50. PubMed ID: 9714327
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the binding of [3H]SR 33805 to the slow Ca2+ channel in rat heart sarcolemmal membrane.
Chatelain P; Dewinkeleer P; Beaufort P; Meysmans L; Clinet M
Eur J Pharmacol; 1994 Apr; 267(2):151-60. PubMed ID: 8050476
[TBL] [Abstract][Full Text] [Related]
10. SR33557, an indolizinsulfone blocker of Ca2+ channels: identification of receptor sites and analysis of its mode of action.
Schmid A; Romey G; Barhanin J; Lazdunski M
Mol Pharmacol; 1989 Jun; 35(6):766-73. PubMed ID: 2543910
[TBL] [Abstract][Full Text] [Related]
11. Fantofarone (SR 33557): cardiovascular actions in anesthetized dogs.
Barthélémy G; Chatelain P; Manning A
Arch Int Pharmacodyn Ther; 1994; 327(2):204-19. PubMed ID: 7979829
[TBL] [Abstract][Full Text] [Related]
12. Fantofarone (SR33557): effects on myocardial oxygen consumption and coronary blood flow.
Hodeige D; Chatelain P; Manning A
Pharmacology; 1994 Jan; 48(1):49-55. PubMed ID: 8309987
[TBL] [Abstract][Full Text] [Related]
13. Fantofarone (SR 33557): effect on post-ischaemic functional recovery in perfused rat hearts.
Manning A; Mouton J; Chatelain P
Eur J Pharmacol; 1992 Sep; 220(2-3):249-58. PubMed ID: 1425996
[TBL] [Abstract][Full Text] [Related]
14. 31P nuclear magnetic resonance study of the effects of the calcium ion channel antagonist fantofarone on the rat heart.
Vander Elst L; Chatelain P; Manning AS; Laruel R; Van Haverbeke Y; Muller RN
Eur J Pharmacol; 1994 Jan; 251(2-3):163-72. PubMed ID: 8149974
[TBL] [Abstract][Full Text] [Related]
15. Synergy between two calcium channel blockers, verapamil and fantofarone (SR33557), in reversing chloroquine resistance in Plasmodium falciparum.
Adovelande J; Delèze J; Schrével J
Biochem Pharmacol; 1998 Feb; 55(4):433-40. PubMed ID: 9514077
[TBL] [Abstract][Full Text] [Related]
16. Effect of SR33557 on intramembrane charge movement in normal and 'muscular dysgenesis' mouse skeletal muscle cells.
Strube C; Shimahara T; Bournaud R
Eur J Neurosci; 1995 Jan; 7(1):41-4. PubMed ID: 7711935
[TBL] [Abstract][Full Text] [Related]
17. Alteration of the [Ca(2+)](i)-force relationship during the vasorelaxation induced by a Ca(2+) channel blocker SR33805 in the porcine coronary artery.
Ieiri S; Hirano K; Nishimura J; Suita S; Kanaide H
Br J Pharmacol; 2000 Dec; 131(8):1597-606. PubMed ID: 11139437
[TBL] [Abstract][Full Text] [Related]
18. Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker.
Chatelain P; Mouton J; Feys G; Laruel A; Manning AS
Cardiovasc Res; 1995 Dec; 30(6):1038-43. PubMed ID: 8746222
[TBL] [Abstract][Full Text] [Related]
19. New drug binding sites in Ca2+ channels.
Spedding M; Kenny B; Chatelain P
Trends Pharmacol Sci; 1995 Apr; 16(4):139-42. PubMed ID: 7610500
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the dihydropyridine receptor and internal Ca2+ stores in myoblast fusion.
Seigneurin-Venin S; Parrish E; Marty I; Rieger F; Romey G; Villaz M; Garcia L
Exp Cell Res; 1996 Mar; 223(2):301-7. PubMed ID: 8601407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
